marijuana stocks news

Weedmaps Editorial Highlights Novus MedPlan

 Novus Acquisition & Development Corp. (OTC PINK:NDEV), a provider of cost-savings healthcare programs through its wholly owned Novus Medical Group subsidiary, today announced that Weedmaps published an editorial discussing Novus MedPlan and its many benefits to medical marijuana patients, as well as a link for medical marijuana patients to enroll in Novus MedPlan.

A brief excerpt from the editorial reads, “We’ve used Novus’ services firsthand and have already saved on products ranging from flower to edibles to hash. If you’re sick of spending too much of your hard-earned money on your medicine and want more reasonable prices, join the Novus movement today.”

The full editorial may be read at: https://news.marijuana.com/news/2015/04/novus-healthcare-saving-medical-marijuana-patients-1000-a-year/

Weedmaps has become a leading marijuana destination with over 680,000 registered members and 10 million page views each month. In addition to these numbers, the organization reaches over 500,000 mobile users, 115,000 YouTube subscribers, and 260,000 social media followers interested in its content and services. The Novus MedPlan editorial will be exposed to this audience via the organization’s website.

“In the cannabis industry’s early stages, it’s important to establish strong alliances,” said Novus Acquisition & Development Corp. CEO Frank Labrozzi. “Weedmaps provides massive visibility and exposure for the Novus MedPlan network and our thousands of MMJ products and non MMJ products, including Charlotte’s Web 30% discount which is getting a lot of attention to membership procurement.”

About Novus

Novus Acquisition & Development Corp. (“Novus”) provides health insurance and related insurance solutions to patients/members in the wellness and medical marijuana industries in states where legal programs exist.

NDEV will work as outside developers and will not cultivate, handle, transport grow, extract, dispense put up for sale, put on the market, vend, deliver, supply, circulate, trade, cannabis or any substances that violates the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The products and statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial changes to the Company. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

Safe Harbor

This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Contacts
Novus Acquisition & Development Corp.
Gary F. Labrozzi
CEO
855-228-7355
Website: www.ndev.biz or www.novusmedicalgroup.com
Email: Frank@ndev.biz

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Tetra Bio-Pharma Inc. (TBPMF) Announces the appointment of Gregory Drohan to its board of directors

Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of…

TRTC goes Supercritical for Cannabinoids

Terra Tech Begins Supercritical CO2 Cannabinoid Extraction, Testing and Formulation Oakland, Oct…

$SIPC Agree on Hemp Supply and Co-Marketing Terms for Hemp Beer

Sipp Industries Subsidiary Major Hemp and Crazy Mountain Brewery Agree on Hemp…